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MicroRNAs (miRNAs) are small non-coding RNA molecules that modulate expression of
the majority of genes by inhibiting protein translation. Growing literature has identified
functional roles for miRNAs across a broad range of biological processes. As such,
miRNAs are recognized as potential disease biomarkers and novel targets for therapies.
While several miRNA-targeted therapies are currently in clinical trials (e.g., for the
treatment of hepatitis C virus infection and cancer), no therapies have targeted miRNAs
in respiratory diseases in the clinic. In this mini-review, we review the current knowledge
on miRNA expression and function in respiratory diseases, intervention strategies to
target miRNA function, and considerations specific to respiratory diseases. Altered
miRNA expression profiles have been reported in a number of respiratory diseases,
including asthma, chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic
pulmonary fibrosis. These include alterations in isolated lung tissue, as well as sputum,
bronchoalveolar lavage fluids and peripheral blood or serum. The observed alterations
in easily accessible body fluids (e.g., serum) have been proposed as new biomarkers
that may inform disease diagnosis and patient management. In a subset of studies,
miRNA-targeted interventions also improved disease outcomes, indicating functional
roles for altered miRNA expression in disease pathogenesis. In fact, direct administration
of miRNA-targeting molecules to the lung has yielded promising results in a number
of animal models. The ability to directly administer compounds to the lung holds
considerable promise and may limit potential off-target effects and side effects caused
by the systemic administration required to treat other diseases.
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INTRODUCTION
MicroRNAs (miRNAs) are small non-coding RNA molecules that inhibit protein translation
from target mRNAs. More than 1000 unique miRNAs are present in the human genome
(Lewis et al., 2005; Berezikov, 2011) and miRNAs are thought to modulate expression of >60%
of genes (Friedman et al., 2009). MiRNAs function across a wide variety of biological
processes and are increasingly recognized as biomarkers for disease diagnosis and potential
therapeutic targets for treatment. In respiratory diseases, there is emerging evidence that altered
miRNA expression modulates disease processes and ultimately disease pathogenesis. In this
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mini-review, we will briefly summarize the current
understanding of how miRNAs are processed and function,
their roles in respiratory diseases and techniques available to
modulate miRNA function in vivo.
MIRNA PROCESSING AND FUNCTION
The mechanisms regulating miRNA expression, processing and
function have been extensively reviewed (Ha and Kim, 2014)
and a schematic of miRNA processing and function is presented
in Figure 1. MiRNAs are commonly encoded either within the
introns of protein-coding genes or as independent genes, and
transcribed by RNA polymerase II (Lee et al., 2004). After
transcription, mature miRNAs are generated through a multi-
step process (Lee et al., 2002). First, the primary transcript
(pri-miRNA) is processed by the nuclear RNase III Drosha-
DGCR8 (DiGeorge syndrome critical region gene 8) complex,
into a ∼65 nucleotide hairpin precursor miRNA (pre-miRNA;
Denli et al., 2004). Pre-miRNAs are exported from the nucleus
into the cytoplasm by exportin 5 and cleaved by the RNase III
enzyme Dicer into a double-stranded miRNA-miRNA∗ duplex
approximately 22 nucleotides (nt) in length (Hutvágner et al.,
2001; Ketting et al., 2001). This miRNA duplex is unwound
by helicases and a mature miRNA is incorporated into the
RNA-induced silencing complex (RISC; Bartel, 2004). The
RISC complex binds target mRNA sequences through partially
complementary binding with the incorporated miRNA (Bartel,
2004; Weinmann et al., 2009).
MiRNAs typically modulate target mRNA levels by binding
to the 3′ untranslated region (UTR) of mRNA transcripts
(Hammond et al., 2001). This occurs through complementary
binding of the highly specific seed sequence at the 5′ end of
a miRNA to the target mRNA (Mallory et al., 2004). Sequence
complementarity between the rest of the miRNA and the target
mRNA is often quite low, allowing individual miRNAs to
target multiple mRNA sequences and making the prediction
of miRNA targets difficult (Lewis et al., 2003; Mallory et al.,
FIGURE 1 | MiRNA processing and function. The primary miRNA transcript (pri-miRNA) is transcribed from DNA and excised by Drosha, to produce the
pre-miRNA. The pre-miRNA is exported to the cytoplasm by exportin-5 and spliced by Dicer to generate a miRNA duplex. The duplex is unwound by helicases and a
mature single-stranded miRNA is assembled into the RISC complex. (A) MiRNA typically modulate target mRNA translation by complementary binding, within the 3′
UTR, 5′ UTR or coding region. New evidence suggests that miRNAs also function by (B) binding of DNA promoters, acting as RNA decoys or through direct binding of
target mRNAs. (C) Mature miRNAs can also be released in exosomes and act on distant cells.
2004; Lim et al., 2005; Liu, 2008). MiRNA:mRNA interactions
repress protein translation and/or reduce target mRNA stability,
resulting in decreased protein translation from the target
mRNA.
New studies are adding increased complexity to our
understanding of how miRNAs function. In addition to binding
target sites within the 3′-UTR of mRNA transcripts, miRNA
can also bind within the 5′-UTR (Lytle et al., 2007), or coding
regions (Forman et al., 2008). Further, a subset of miRNAs
increase target expression through a number of mechanisms
(Vasudevan et al., 2007), including binding DNA promoters
(Place et al., 2008), acting as RNA decoys (Eiring et al.,
2010) or through binding of target mRNAs (Ørom et al.,
2008). MiRNAs can also be released from expressing cells and
detected in exosomes in the circulation allowing communication
between neighboring and distant cell populations (Mitchell et al.,
2008; Liu et al., 2010a; Redis et al., 2012). As miRNAs are
single-stranded RNA molecules, they may also activate immune
cells following binding to Toll-like receptors (TLRs) either
as part of their function, or as an unintended consequence
following administration (Fabbri et al., 2012; Lehmann et al.,
2012).
MIRNA EXPRESSION IN RESPIRATORY
DISEASES
Key roles for miRNAs in normal lung development and
respiratory diseases have been extensively reviewed (Plank
et al., 2013; Rupani et al., 2013; Booton and Lindsay, 2014).
These include extensive reviews of specific respiratory diseases
including asthma (Tay et al., 2014), chronic obstructive
pulmonary disease (COPD) (De Smet et al., 2015), cystic fibrosis
(CF) (Sonneville et al., 2015), and idiopathic pulmonary fibrosis
(IPF) (Pandit et al., 2011), as well as lung cancer (Lin et al.,
2010; Rusek et al., 2015). For the purpose of this mini-review, we
will briefly summarize recent findings on miRNA expression and
function in each of these diseases (Table 1).
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TABLE 1 | MicroRNA profiling studies and individual microRNAs identified in respiratory diseases.
Respiratory diseases miRNA expression profiling Individual miRNAs
Asthma Patient samples:
Bronchial epithelium (Jardim et al., 2012; Solberg et al., 2012)
BALF exosomes (Levänen et al., 2013)
Peripheral blood (Panganiban et al., 2012; Yamamoto et al., 2012)
Blood: child population (Liu et al., 2012)
Airway T cells (Simpson et al., 2014)
Mouse models of allergic airways disease:
Three models (Garbacki et al., 2011)
Deep sequencing lung (Polikepahad et al., 2010)
Functional roles:
let-7 (Polikepahad et al., 2010)
miR-9 (Li et al., 2015)
miR-19a (Simpson et al., 2014)
miR-21 (Lu et al., 2009, 2011)
miR-106a (Sharma et al., 2009, 2012)
miR-126 (Mattes et al., 2009; Collison et al., 2011a)
miR-145 (Collison et al., 2011b)
miR-155 (Malmhäll et al., 2014; Okoye et al., 2014)
miR-221 (Qin et al., 2012)
COPD Smoking-induced changes:
Isolated lung macrophages (Graff et al., 2012; Gross et al., 2014)
Lung tissues (Izzotti et al., 2009a,b)
Bronchial epithelium (Schembri et al., 2009)
Lung tissue:
Smokers (COPD vs. healthy) (Ezzie et al., 2012)
Related to emphysema severity (Savarimuthu Francis et al., 2014)
Regions related to emphysema (Christenson et al., 2013)
Biomarkers:
Sputum (Van Pottelberge et al., 2011)
Exhaled breath condensates (Pinkerton et al., 2013)
Biomarkers:
Serum miR-7 (Akbas et al., 2012)
Serum miR-21, -181a (Xie et al., 2014)
In vitro:
miR-146a (Sato et al., 2010)
miR-199a-5p (Mizuno et al., 2012; Chatila et al., 2014; Hassan et al.,
2014)
Functional roles:
miR-135b (Halappanavar et al., 2013)
miR-144, -101 (Hassan et al., 2012a)
CF Endobronchial brushings (Oglesby et al., 2010) Targeting CFTR:
miR-101, -494 (Megiorni et al., 2011)
miR-138 (Ramachandran et al., 2012)
miR-145, -223, -494 (Oglesby et al., 2013)
miR-509-3p, -494 (Ramachandran et al., 2013)
Inflammation:
miR-17 (Oglesby et al., 2015)
miR-126 (Oglesby et al., 2010)
miR-145 (Megiorni et al., 2013)
miR-155 (Bhattacharyya et al., 2011)
IPF Patient lungs (Pandit et al., 2010)
Serum (Li et al., 2014)
Functional roles:
Let-7 (Pandit et al., 2010)
miR-21 (Liu et al., 2010b; Li et al., 2013)
miR-26a (Liang et al., 2014)
miR-29 (Cushing et al., 2011)
miR-155 (Pottier et al., 2009)
miR-200 (Yang et al., 2012)
miR-326 (Das et al., 2014)
miR-486 (Ji et al., 2015)
COPD, chronic obstructive pulmonary disease, CF, cystic fibrosis, IPF, idiopathic pulmonary fibrosis.
Asthma
Many studies have performed miRNA profiling on samples
from patients with asthma. Profiling of bronchial epithelial
cells identified 60–200 differentially expressed miRNAs (Jardim
et al., 2012; Solberg et al., 2012), and isolated exosomes from
bronchial alveolar lavage fluids exhibited changes in 24 miRNAs
(Levänen et al., 2013). Profiling of peripheral blood samples
revealed alterations in miRNA expression patterns, with miR-
192 notably decreased (Yamamoto et al., 2012), and alterations
in miR-124, -26a, let-7a, and let-7d (Panganiban et al., 2012).
Profiling of circulating lymphocytes also identified upregulation
of miR-221 and miR-485-3p in asthmatic children compared to
healthy controls (as well as in an ovalbumin (OVA)-induced
mouse model of asthma; Liu et al., 2012). Profiling of airway
T cells also revealed increased levels of miR-19a in patients
with asthma, with functional roles in TH2 cytokine production
(Simpson et al., 2014).
A growing number of studies have also demonstrated
alterations and functional roles for miRNAs in mouse models
of allergic airways disease. A profiling study using three
murine models of allergic inflammation identified a number
of altered miRNAs, including miR-29b, -29c, -146b, -223, -
483, -574-5p, -672, and -690 (Garbacki et al., 2011). Deep
sequencing of mouse lungs revealed dynamic changes in miRNA
expression following OVA-induced allergic airway inflammation
and demonstrated high levels of let-7 family members in
OVA-challenged lungs (Polikepahad et al., 2010). Inhibition
of let-7 family members reduced the allergic phenotype and
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IL-13 expression (Polikepahad et al., 2010). MiR-21 expression
is increased in several models of experimental asthma (Lu
et al., 2009) and mir-21 gene deletion reduced TH2 responses
and decreased eosinophilia in an ovalbumin (OVA)-induced
asthma model (Lu et al., 2011). Inhibition of miR-106a also
reduced features of disease including AHR, inflammation and
fibrosis (Sharma et al., 2009, 2012). Mir-155-deficient mice also
have decreased asthma disease severity (Malmhäll et al., 2014),
which was attributed to altered T cell function (Okoye et al.,
2014). Inhibition of miR-221 in a mouse model of asthma also
suppresses airway inflammation (Qin et al., 2012).
Our group demonstrated that antagomir-mediated inhibition
of miR-126 significantly reduced airway hyperreactivity,
eosinophil recruitment, mucus hypersecretion, and TH2 cell
activation (Mattes et al., 2009). However, while inhibition of
miR-126 reduced eosinophil infiltration in chronic asthma
models, it failed to inhibit inflammation and airway remodeling
(Collison et al., 2011a). Expression of miR-145, miR-21, and
let-7b were increased after house dust-mite (HDM) exposure
and inhibition of miR-145 (but not miR-21 or let-7b) suppressed
airways inflammation (Collison et al., 2011b). Recently, we
also demonstrated that inhibition of miR-9 restored steroid
sensitivity and dampened airways inflammation in an otherwise
steroid-resistant airways disease model (Li et al., 2015).
Respiratory bacterial and viral infections are also associated
with asthma onset and disease exacerbations (reviewed in Falsey
and Walsh, 2000; Hansbro et al., 2004; Friedlander and Busse,
2005; Piedimonte, 2013; Starkey et al., 2013; Choroszy-Król
et al., 2014; Leigh and Proud, 2015). For example, Haemophilus
influenzae bacterial infection is linked to both exacerbations and
disease severity in patients with asthma (Wood et al., 2010).
Importantly, key roles for miRNA functions are recognized
in responses to respiratory infections [reviewed for virus
(Globinska et al., 2014) and bacterial infections (Staedel and
Darfeuille, 2013)]. For example, inhibition of miR-328 promoted
clearance ofH. influenzae, even in the context of steroid-induced
immunosuppression (Tay et al., 2015). Thus, modulation of
miRNA function may impact asthma severity by altering the
course of respiratory infections and miRNAs may also serve
as therapeutic targets for the management of infection-induced
asthma exacerbation.
Chronic Obstructive Pulmonary Disease
A growing number of studies have also assessed miRNA
expression in COPD patients. As smoking is a major contributing
factor for COPD development, many studies have also assessed
impacts of cigarette smoke exposure alone. However, these
studies have not yet assessed functional impacts in COPD.
Cigarette smoke reduced global miRNA expression, in human
alveolar macrophages isolated from smokers compared to non-
smokers (Graff et al., 2012; Gross et al., 2014) and lung tissue
from smoke-exposed mice or rats (Izzotti et al., 2009a,b). In
isolated bronchial airway epithelium from smokers, 28 miRNAs
were differentially expressed, including miR-218 (Schembri et al.,
2009). Profiling of miRNAs from different lung regions in
smokers with COPD revealed subsets of miRNAs that correlated
with regional emphysema severity (Christenson et al., 2013). In a
comparison of lung tissue from smokers with COPD, to smokers
without COPD, miRNA profiling revealed increased levels of 57
miRNAs, with 13 decreased (Ezzie et al., 2012). Further, altered
miRNA expression in lung tissue was detectable between COPD
patients based on emphysema severity (Savarimuthu Francis
et al., 2014).
MiRNA expression has been proposed as an accessible
biomarker of COPD disease. The ratio of serum miR-21 to -181a
was predictive for COPD in asymptomatic heavy smokers (Xie
et al., 2014). Decreased serum levels of miR-20a, -28-3p, -34c-5p,
and -100, and increased miR-7 were also detected in COPD
patients (Akbas et al., 2012). Similarly, altered miRNA expression
in sputum (Van Pottelberge et al., 2011) and exhaled breath
condensates (Pinkerton et al., 2013) have been detected in
patients with COPD.
A number of individual miRNAs have also been assessed
in samples isolated from COPD patients. MiR-146a induction
following ex vivo cytokine activation is reduced in fibroblasts
from COPD patients that smoke, compared to fibroblasts from
smokers without COPD (Sato et al., 2010). MiR-199a-5p was
decreased in peripheral blood monocytes from symptomatic
COPD patients (Hassan et al., 2014), with decreases also observed
in circulating regulatory T cells (Chatila et al., 2014). However,
levels of miR-199-5p were increased in total lung tissues (Mizuno
et al., 2012). In mouse models, miR-135b was increased in lungs
from smoke-exposed mice, which required interleukin 1 (IL-1)-
R1 expression and acted as a negative regulator of IL-1 activation
and signaling (Halappanavar et al., 2013). In lungs from smoke-
exposed mice and COPD patients, miR-144 and -101 were also
both increased, and suppressed expression of their target CF
transmembrane conductance regulator (CFTR) (Hassan et al.,
2012a).
Cystic Fibrosis
Cystic fibrosis is caused by mutations in the CFTR gene. Despite
this simple cause, significant heterogeneity exists between CF
patients, suggesting potential roles for epigenetic regulation,
including miRNA alterations (Cutting, 2010).
Most work on miRNA function in CF has assessed direct
impacts on CFTR expression. Increased miR-101 and -494
repressed CFTR expression in cell lines in vitro (Megiorni et al.,
2011). Further, miR-138 overexpression increased levels of CFTR
(via suppression of its target SIN3 transcription regulator family
member A, in CF airway epithelial cells (Ramachandran et al.,
2012). MiR-145, -223, and -494 were increased in CF bronchial
brushings, and directly regulated CFTR expression in vitro
(Oglesby et al., 2013). MiR-509-3p and -494 were also increased
in primary cultured airway epithelia from CF patients, vs.
non-CF controls, and cooperatively repressed CFTR expression
(Ramachandran et al., 2013).
Several studies have also assessedmiRNA-mediated regulation
of inflammation in CF patients. MiR-17 was decreased in CF
bronchial brushings, resulting in increased expression of its pro-
inflammatory target, IL-8 (Oglesby et al., 2015). MiR-126 was
downregulated in bronchial epithelial cells fromCF patients, with
significant increases in target of myb protein 1, which modulates
inflammatory responses (Oglesby et al., 2010). MiR-155 was
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increased in mutant CFTR epithelial cell lines, contributing to
increased pro-inflammatory IL-8 release (Bhattacharyya et al.,
2011). Finally, elevated miR-145 levels negatively correlated with
its target SMAD family member 3 in nasal epithelial cells fromCF
patients, potentially regulating downstream transforming growth
factor, beta 1 (TGF-β1) inflammatory pathways (Megiorni et al.,
2013).
In addition to direct effects on CFTR and inflammation,
bacterial infections worsen CF disease symptoms and contribute
to long-term airway remodeling. Thus, impacts of miRNA
function on anti-bacterial immunity may also regulate disease
progression and shape disease management strategies.
Idiopathic Pulmonary Fibrosis
IPF is a chronic fibrosing interstitial lung disease with unknown
causes. Initial profiling of IPF lungs revealed that 10% of lung-
expressed miRNAs were altered, compared to normal controls
(Pandit et al., 2010). Profiling of circulating serum miRNAs in
patients with IPF revealed altered expression of miR-21, -155,
and -101-3p associated with clinical features of disease (Li et al.,
2014). MiR-21 expression was increased in the serum of IPF
patients, and levels correlated with decreases in lung function (Li
et al., 2013). Let-7 was also significantly downregulated in IPF
lungs and may contribute to fibrosis through regulation of high
mobility group A2 (Pandit et al., 2010).
Little is known aboutmiRNA function in IPF and importantly,
much of the functional data has been inferred from chemically-
induced mouse models of lung fibrosis. MiR-29 was reduced
in mouse models, as seen in IPF lung samples (Pandit et al.,
2010), and knockdown in human fetal lung fibroblasts increased
fibrosis-associated gene expression (Cushing et al., 2011). MiR-
21 expression was increased in myofibroblasts from IPF lungs
and inhibition in mouse fibrosis models dampened disease
severity (Liu et al., 2010b). MiR-155 was increased in mouse
fibrosis models (Pottier et al., 2009), and may modulate fibrosis
through regulation of angiotensin II type I receptor, which is
increased in IPF lungs (Königshoff et al., 2007). MiR-200 family
members were reduced in mouse models of lung fibrosis and
restoration of miR-200c inhibited fibrosis (Yang et al., 2012).
MiR-26a was decreased in fibrosis models and inhibition caused
pulmonary fibrosis, while overexpression repressed fibrotic
disease (Liang et al., 2014). MiR-326 was also decreased in
mouse fibrosis models and human IPF lung samples, and
administration of miR-326 mimics inhibited TGF-β expression
and dampened fibrosis (Das et al., 2014). MiR-486-5p was
decreased in lung tissues of patients with IPF and overexpression
of miR-486-5p limited fibrosis in mouse models (Ji et al.,
2015).
Lung Cancer
The impacts of miRNA dysregulation on cancer initiation and
progression have been extensively studied and reviewed (Hayes
et al., 2014; Lin and Gregory, 2015). A summary of the proposed
roles for miRNAs in cancer is beyond the scope of this mini-
review and we direct readers to reviews that have summarized
miRNA functions in lung cancers specifically (Lin et al., 2010;
Rusek et al., 2015).
TARGETING MIRNA FUNCTION IN
THERAPY
The studies described have revealed changes in miRNA
expression in respiratory diseases and key functions across
a range of disease processes. Interestingly, miRNA-targeted
interventions modified disease pathogenesis in pre-clinical
disease models, for a small subset of the miRNAs identified in
each disease.
Based on similar findings in other fields, many
biopharmaceutical companies are now targeting miRNAs
using novel therapeutics. The first drug to inhibit a specific
miRNA (miR-122) entered Phase II clinical trials in 2010 for the
treatment of hepatitis C virus infection (Janssen et al., 2013).
The first drug to increase a specific miRNA (miR-34 mimic;
MRX34) entered Phase I clinical trials in 2013, for the treatment
of advanced hepatocellular carcinoma (Bouchie, 2013). However,
no clinical trials have yet assessed the impacts of miRNA-targeted
strategies in respiratory diseases.
PHARMACOLOGICAL ACTIVATION OF
MIRNA FUNCTION
One approach to alter miRNA function in vivo is through
administration of double-stranded synthetic miRNA
oligonucleotides, termed mimics, which have been used
extensively in cancer studies (Henry et al., 2011). These double-
stranded molecules are processed by the endogenous miRNA
processing machinery, integrated into the RISC complex and
dampen target mRNA translation. A main limitation of this
approach is the effective delivery of mimic molecules into target
cells.
One strategy to improve cell targeting is the coupling
of mimics to antibody-coated nanoparticles, as used in
neuroblastoma (Liu et al., 2011). Another approach (used in
the current MRX34 clinical trial), is encapsulation of mimic
molecules in liposome-based delivery system to facilitate target
cell uptake (Bouchie, 2013).
An alternative approach that stably increases miRNA levels is
delivery of miRNA expression vectors (Stegmeier et al., 2005).
This approach can yield stable, long-term miRNA expression
and provides the potential to target vectors to specific cell types
or enforce cell-type specific miRNA expression using specific
promoters.
PHARMACOLOGICAL INHIBITION OF
MIRNA FUNCTION
To inhibit target miRNAs, oligonucleotide inhibitors with
complementary sequences to the miRNA of interest can be used
(anti-miRs). These molecules are often comprised of locked
nucleic acid backbones with specific modifications to increase
stability in vivo (Lennox and Behlke, 2011). One specific category
of inhibitor, termed antagomirs, is further modified with a 2′-O-
methyl linkage and phosphorothioate modification to improve
binding efficiency and prevent nuclease degradation (Krützfeldt
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et al., 2005). Anti-miR treatments interfere with target miRNA
function, increasing translation of miRNA-targeted mRNAs.
Antagomir-mediatedmiRNA-silencing in vivo is dose-dependent
and can last for several weeks after a single administration
(Krützfeldt et al., 2005).
Another strategy to inhibit miRNA function is the use of
“miRNA sponges.” MiRNA sponges are transgenes that encode
RNA molecules comprised of multiple tandem miRNA target
sites (Ebert et al., 2007). The repeated target sequences compete
with endogenous mRNA targets for RISC binding, reducing
the impact of a specific miRNA on its intended target (Ebert
et al., 2007). This approach has been used extensively in vitro
and in preclinical animal models. However, this approach also
requires delivery of a transgene-encoding vector to achieve stable
inhibition (Gentner et al., 2009).
CONSIDERATIONS FOR
MIRNA-TARGETED INTERVENTIONS IN
RESPIRATORY DISEASES
There are a number of considerations and issues to consider
when modulating miRNA expression in general, and more
specifically in lung disease (reviewed in Hassan et al., 2012b).
Individual miRNAs modulate expression of multiple mRNA
targets and interfering with single miRNAs can have broad effects
onmultiple cellular pathways. For this reason, therapies targeting
individual miRNAs can have broader impacts than traditional
single-molecule/single-target approaches. Further, compared to
short-interfering RNA approaches, miRNA targeting may have
broader effects on more mRNAs, but more moderate effects on
each individual mRNA (Baker, 2010). This can be beneficial, as
individual miRNAs often regulatemultiple genes in a related gene
network. However, the alteration of multiple downstream targets
also increases the likelihood of undesired side effects, particularly
if systemic drug delivery is used.
The simplest approaches to modulate miRNA levels are
through administration of “naked” nucleic acids (either mimic
or anti-miR). This approach provides the advantage of being
able to tailor dosing and withdraw treatment if complications
arise. In respiratory diseases, direct tissue administration by
aerosol provides targeted delivery to lung tissue, with minimal
dissemination into the circulation and systemic tissues. This
is likely to limit side effects, compared to systemic delivery.
However, this also means that these therapies will only be
effective if altering miRNA function specifically within the
lung is sufficient to dampen disease processes. Even with
direct administration into the lung, efficient delivery to target
cell populations remains difficult, as seen in siRNA-based
therapies (Lam et al., 2012). For example, we observe cell type-
specific differences in antagomir distribution following intranasal
administration in vivo, with efficient uptake in myeloid cell
populations and poor targeting of lymphocytes, which was also
replicated in vitro (Plank et al., 2015).
More complex treatment strategies requiring stable expression
and viral delivery systems (e.g., sustained miRNA delivery or
miRNA sponges) add additional complications relating to the
expression vector itself. Viral delivery platforms have been
associated with direct toxicity, increased risks associated with
genomic integration events and the inability to discontinue
treatment if problems do arise (Ibrahim et al., 2011). A further
drawback, specific to miRNA modulation using viral delivery
systems, is toxicity induced by the overwhelming of the exportin-
5 pathway following enforced miRNA expression (Castanotto
et al., 2007).
CONCLUSIONS
Increasing numbers of publications have identified differences
in miRNA expression and functional roles for miRNAs
across a range of respiratory diseases. MiRNAs have been
proposed as biomarkers of disease and potential novel
therapeutic targets for treatment. In respiratory diseases,
direct administration of miRNA-targeting drugs into the
lungs may allow tissue-specific targeting, while limiting side
effects resulting from systemic delivery. Continued mechanistic
studies are required to optimize drug delivery systems and
demonstrate acceptable efficacy and safety for translation into
the clinic. While miRNA-targeting approaches hold promise,
no studies have yet assessed impacts in human respiratory
diseases.
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